Tag Archives: AI drug discovery

March 8, 2021
In The News
Read Article
January 12, 2021
In The News
Read Article
December 21, 2020
In The News

After raising $123 million this past summer to fuel its artificial-intelligence-based drug design work, Atomwise has helped launch a new company focused on uncovering treatments in immuno-oncology.

Read Article
December 18, 2020
In The News

A2i Therapeutics secures seed funding from FutuRx and its investors – Johnson & Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority – to develop novel small molecule immuno-oncology agents.

Read Article
December 18, 2020
FeaturedPress Release

A2i Therapeutics secures seed funding from FutuRx and its investors – Johnson & Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority – to develop novel small molecule immuno-oncology agents. SAN FRANCISCO, CA and NESS ZIONA, Israel – December  18, 2020 – Atomwise, the leader in using artificial […]

Read Article
November 30, 2020
Broadcast
Read Article